Tag Archives: Amgen

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Posted in Global, Strategy | Also tagged , , , , , , | Leave a comment

AbbVie, Amgen, and Roche Most Exposed to Biosimilar Competition

While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market.
Posted in Biotech, Gene therapy | Also tagged , , , | Leave a comment

Forbes Health Summit: Industry Leaders Ponder the New World of Consumer-Driven Care

In health care, it is the lowly consumer who is now calling the shots, driving product and process innovation in areas ranging from electronic medical records [EMR] to retail health clinics. This was the main theme among discussants at the Forbes magazine Healthcare Summit held here in New York on October 10.  The central question:  […]
Posted in leadership, Meetings, patient education, R&D, Strategy | Also tagged , , , , , , , , , , | Leave a comment

Battle Escalates over 340B Drug Pricing Program

What was once an obscure federal policy for providing low-cost drugs to safety-net hospitals has grown into a program that requires extensive discounting to one-third of the nation’s hospitals and health clinics. Pharma companies are pushing back, heightening tensions between “covered entities” that qualify for greatly reduced prices on medicines under 340B — and manufacturers […]
Posted in healthcare, pricing, Regulatory, Sales, Strategy | Also tagged , , , , , , , , , , , , , | Leave a comment

Biomedical Innovation in Trouble

The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by […]
Posted in Biotech, FDA, healthcare, leadership, R&D, Technology | Also tagged , , , , | 3 Comments
  • Categories

  • Meta